← Back to Search

Dopamine Antagonist

Metoclopramide for Cesarean Section

Phase 4

Waitlist Available

Led By Jennifer Banayan, MD

Research Sponsored by Northwestern University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Healthy (ASA Physical Status 2)

Age >18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 48 hours

Awards & highlights

Study Summary

This trial will compare gastric volumes of women who receive metoclopramide versus placebo prior to scheduled cesarean delivery.

Who is the study for?

This trial is for healthy, non-obese women over 18 years old who are at full term (>37 weeks) with a single pregnancy and scheduled for a cesarean delivery without having eaten (NPO). They should not be in labor, have multiple gestations, GI tract abnormalities or surgeries, renal impairment, or systemic diseases like diabetes.Check my eligibility

What is being tested?

The study aims to compare gastric volumes in pregnant women undergoing cesarean sections who receive either metoclopramide or a placebo. The goal is to determine if metoclopramide reduces the risk of aspiration by decreasing stomach volume.See study design

What are the potential side effects?

Potential side effects from metoclopramide may include drowsiness, restlessness, fatigue and sometimes more serious effects like movement disorders. However, individual reactions can vary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am generally healthy with mild systemic disease.

Select...

I am older than 18 years.

Select...

My BMI is under 40.

Select...

I am older than 18 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 48 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~48 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in gastric volume (mL)

Secondary outcome measures

Adverse events

Incidence (number of events) of nausea and vomiting

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Group 1 Study Drug MetoclopramideActive Control1 Intervention

Intravenous administration of 10 mg metoclopramide

Group II: Group 2 Study Drug PlaceboPlacebo Group1 Intervention

Intravenous administration of sterile normal saline

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor

1,585 Previous Clinical Trials

917,152 Total Patients Enrolled

Jennifer Banayan, MDPrincipal InvestigatorNorthwestern University

Media Library

Metoclopramide (Dopamine Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05033041 — Phase 4

Cesarean Section Research Study Groups: Group 1 Study Drug Metoclopramide, Group 2 Study Drug Placebo

Cesarean Section Clinical Trial 2023: Metoclopramide Highlights & Side Effects. Trial Name: NCT05033041 — Phase 4

Metoclopramide (Dopamine Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05033041 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many volunteers is this clinical trial accommodating?

"Verified. Clinicaltrials.gov lists this clinical trial as open, which was initially posted on October 20th 2021 and last revised on the 22nd of the same month. This study is recruiting 72 participants from a single location."

Answered by AI

Is this experiment still accepting new participants?

"Indeed, the information hosted on clinicaltrials.gov affirms that this trial is actively seeking participants. Initially posted on October 20th 2021, it was last revised two days later and need 72 volunteers from a single medical centre."

Answered by AI

What medical conditions is Group 1 Study Drug Metoclopramide typically used to treat?

"The therapeutic procedure is often treated with Group 1 Study Drug Metoclopramide, which can also effectively ameliorate gastroparesis, gastric motility disorder and facilitate the radiologic procedures linked to gastric emptying."

Answered by AI